The clinical effectiveness of 311c90 in the acute treatment of migraine

European Neurology

Volumn 36, Issue , 1996, Pages 4-7

  Ferrari, Michel D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

311C90; Efficacy; Headache recurrence; Headache response

Indexed keywords

ANTIMIGRAINE AGENT; SEROTONIN; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN; ZOLMITRIPTAN;

ARTICLE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; MIGRAINE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENCE RISK; TIME;

DOUBLE-BLIND METHOD; HUMANS; MIGRAINE DISORDERS; MULTICENTER STUDIES; OXAZOLES; OXAZOLIDINONES; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS; TIME FACTORS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 0030049429     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000119096     Document Type: Article

References (13)

1. Plosker GL, McTavish D: Sumatriptan: A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47:622-651
2. Goadsby PJ, Edvinsson L: Peripheral and central trigeminovascular activation in cat is blocked by serotonin (5-HT)-1D receptor agonist 311C90. Headache 1994;34:394-399.
3. Mills A, Rhodes P, Martin GR: [H]3IIC90 binding sites in cat brain stem: implications for migraine treatment. Cephalalgia 1995; 15 (suppl 14): 116.
4. Goadsby PJ, Hoskin KL: Trigeminal neuronal activity is inhibited by intravenous administration of 311C90 in the cat. Cephalalgia 1995:15 (suppl 14): 106.
5. Lacey LF, Hussey EK, Fowler PA: The single dose pharmacokinetics of sumatriptan in healthy volunteers. EurJ Clin Pharmacol 1995: 47:543-548.
6. Schoenen J, Caekebekc P, Louis G, Monseu G, Phillips S, Pierre P: An open study to investigate the absorption and tolerability of oral 311C90 and to obtain a preliminary indication of efficacy in migraine patients. In: Proceedings of the 10th Migraine Trust Symposium, F. Clifford Rose ed. New Advances in Headache Research. 4 London. Smith-Gordon 1994: 11-12.
7. Thomsen L, Lassen L, Bendtsen L, Daugaard D, Dixon R, Olesen J: An open, crossover study to compare the absorption of a 10 mg oral dose of 311C90 during and outside a migraine attack and to obtain a preliminary indication of efficacy in migraine. In: Proceedings of the 10th Migraine Trust Symposium. F. Clifford Rose ed. New Advances in Headache Research, 4 London. Smith-Gordon 1994: 13-14.
8. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD: 31IC90, a new central and peripherally acting 5-HT, receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose range finding study. Neurology 1996;46:522-526.
9. Dahlöf C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, Wilkinson M, Sweet RM, Klein KB: A multinational.double-blind, placebo-controlled, dose range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache 1995:35:292.
10. Rapoport AM, Cady RK, Mathew NT, Ramadan NM, Taylor FR, Saper JR, Earl NL. Brown DL for the US 31IC90 Dose Ranging Study Group: Optimizing the oral dose of 3IIC90 in the acute treatment of migraine. Cephalalgia 1995; 15(suppl 14):221.
11. Lowy MT, Kench S, Miles P: lor The International 31IC90 Long-Term Study Group: Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine. Cephalalgia 1995:15(suppl 14):222.
12. Pilgrim AJ: Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991;31:295-299.
13. Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988;8(suppl 7):1-96.